A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 3 Study Comparing Riliprubart and Intravenous Immunoglobulin (IVIg) in People with CIDP
Sponsor: Sanofi
Enrolling: Male and Female Patients
IRB Number: AAAV1423
U.S. Govt. ID: NCT06290141
Contact: Jorge Cabrera, CRC: 212-305-7462 / jec2273@cumc.columbia.edu
Additional Study Information: This is a Phase 3, randomized, double blind, study evaluating efficacy and safety of riliprubart versus intravenous immunoglobulin (IVIg) in participants with chronic inflammatory demyelinating polyneuropathy. Overall the study will last about 109 weeks (2 years) . Participants must be 18 years old at the time of signing the informed consent form.
Investigator
Thomas Brannagan, MD
Do You Qualify?
Are you 18 years old? Yes No
Do you have CIDP or possible CIDP? Yes No
Have you responded to IVIg in the past 5 years? Yes No
Have you been on a stable maintenance dosage of IVIg? Yes No
Do you have poorly controlled diabetes (HbA1c 7% at the Screening visit)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Jorge Cabrera, CRC
jec2273@cumc.columbia.edu
212-305-7462
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE